Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sits in the top decile of US sponsors by registered trial count (#204 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University: 138 sponsored US clinical trials, 4 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sponsors 138 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 101 completed. 4 of these trials are in Phase 3-4 (later-stage) and 93 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreatic Cancer, with 2 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University ranks in the top decile of sponsors by registered trial count (#204 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
101 of 129 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
138 total, page 3 of 3
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
NCT01341301
Desensitizing Distressing Recollections in Cancer Patients
NCT02760524
Treatment of Sickle Cell Anemia With Stem Cell Transplant
NCT01350232
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
NCT00983307
Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer
NCT00954525
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
NCT00838929
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
NCT00994643
Fatigue and Pancreas and Bile Duct Cancer Study
NCT00902759
Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer
NCT00806611
Robotic Seed Implantation for Prostate Cancer Brachytherapy
NCT01341288
A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients
NCT00699842
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
NCT01315132
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
NCT00639262
Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)
NCT00626444
TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
NCT01349075
Contrast Enhanced Transrectal Ultrasonography (TRUS) to Assess Prostatic Vascularity After Radiotherapy (XRT)
NCT00635167
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
NCT00437372
Use of Cone Beam Kilovoltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer
NCT00358007
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
NCT00405405
Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer
NCT00398281
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
NCT01162096
Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
NCT00330044
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
NCT00429143
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
NCT00410423
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
NCT00408928
Using Intensity Modulated Radiation Therapy (IMRT) for Brain Metastases
NCT00328575
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
NCT00329589
Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin
NCT00716560
Comparing Two Forms of Head Immobilization for Stereotactic Radiotherapy
NCT00328510
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
NCT00661622
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
NCT00429416
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
NCT00328458
ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer
NCT00328562
Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer
NCT00328614
Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer
NCT00328783
A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation
NCT00429039
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00003268
Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
NCT00003089
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 41 |
| Phase 3 | 4 |
What is open in the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University pipeline
4 recruiting of 138 indexed (3% open); 101 completed (73%).
Phase mix: 4 late (III/IV) vs 93 early (I/II) (early-phase heavy).
Top condition: Pancreatic Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University: open-pipeline peers nationwide
Peers matched on 138 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 138 trials (± recruiting share)
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Barbara Ann Karmanos Cancer Institute · 139 trials · 12% recruiting
- Centers for Disease Control and Prevention · 139 trials · 2% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Merz North America · 3% recruiting · 35 trials
- VIVUS · 3% recruiting · 35 trials
- Idorsia Pharmaceuticals · 3% recruiting · 34 trials
- Klein Buendel · 3% recruiting · 34 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University page
138 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University or any single study.
- 4 of Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pancreatic Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreatic Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University pipeline card: 138 registered trials from official public datasets.Report a data error.